Transport Kinetics of Four- and Six-coordinate Platinum Compounds in the Multicell Layer Tumour Model

Overview

Journal Br J Cancer

Specialty Oncology

Date 2007 Jun 21

PMID 17579620

Citations 9

Authors

S Modok

R Scott

R A Alderden

M D Hall

H R Mellor

S Bohic

T Roose

T W Hambley

R Callaghan

Affiliations

Soon will be listed here.

Abstract

Four-coordinate (Pt(II)) platinum-based anticancer drugs are widely used in primary or palliative chemotherapy and produce considerable efficacy in certain clinical applications, for example testicular cancer. However, in many cancers the Pt(II) drugs are beset by poor efficacy mainly due to suboptimal pharmacokinetic properties. Consequently, the six-coordinate (Pt(IV)) class of Pt drugs were developed to improve platinum efficacy by (i) increasing stability, (ii) reducing reactivity, (iii) increasing lipophilicity, and (iv) nuclear targeting. However, comparatively little information is available on the pharmacokinetic properties of these compounds within solid tumour tissue. In the present study, the distribution and fluxes of [(14)C]-labelled [PtCl(2)(en)] (where en stands for ethane-1,2-diamine) and cis,trans-[PtCl(2)(OH)(2)(en)] drugs were determined in the multicell layer (MCL) tumour model comprising colon cancer cells. Flux data were analysed by mathematical modelling of drug diffusion and cellular uptake in the transport system. The flux of the Pt(IV) compound through the MCL was not significantly different to that of the Pt(II) drug nor were the diffusion coefficient or tissue uptake; the latter confirmed with elemental imaging analysis by synchrotron radiation induced X-ray emission. However, the flux of the Pt(IV) through the MCL was increased by hydrostatic pressure, thereby demonstrating the potential to target cancer cells further away from the vessels with six-coordinate platinum drugs.

Citing Articles

The Effect of Dynamic, In Vivo-like Oxaliplatin on HCT116 Spheroids in a Cancer-on-Chip Model Is Representative of the Response in Xenografts.

Komen J, van Neerven S, Bossink E, de Groot N, Nijman L, van den Berg A Micromachines (Basel). 2022; 13(5).

PMID: 35630206 PMC: 9146796. DOI: 10.3390/mi13050739.

Understanding nanoparticle flow with a new in vitro experimental and computational approach using hydrogel channels.

Boutchuen A, Zimmerman D, Arabshahi A, Melnyczuk J, Palchoudhury S Beilstein J Nanotechnol. 2020; 11:296-309.

PMID: 32117668 PMC: 7034222. DOI: 10.3762/bjnano.11.22.

Peri-tumor administration of 5-fluorouracil sol-gel using a hollow microneedle for treatment of gastric cancer.

Jung Y, Koo D, Yang J, Lee H, Park J, Park J Drug Deliv. 2018; 25(1):872-879.

PMID: 29608119 PMC: 6058607. DOI: 10.1080/10717544.2018.1455760.

A fluorescent oxaliplatin derivative for investigation of oxaliplatin resistance using imaging techniques.

Kalayda G, Kullmann M, Galanski M, Gollos S J Biol Inorg Chem. 2017; 22(8):1295-1304.

PMID: 29043454 DOI: 10.1007/s00775-017-1502-z.

In vitro and in vivo antitumor effects of the VO-chrysin complex on a new three-dimensional osteosarcoma spheroids model and a xenograft tumor in mice.

Leon I, Cadavid-Vargas J, Resasco A, Maschi F, Ayala M, Carbone C J Biol Inorg Chem. 2016; 21(8):1009-1020.

PMID: 27696106 DOI: 10.1007/s00775-016-1397-0.

References

Lindauer E, Holler E . Cellular distribution and cellular reactivity of platinum (II) complexes. Biochem Pharmacol. 1996; 52(1):7-14. DOI: 10.1016/0006-2952(96)00106-2. View

Nishikawa K, Newman R, Murray L, Khokhar A, Rosenblum M . Detection of cellular platinum using the monoclonal antibody 1C1. Mol Biother. 1990; 2(4):235-41. View

Wang D, Lippard S . Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005; 4(4):307-20. DOI: 10.1038/nrd1691. View

Mellor H, Snelling S, Hall M, Modok S, Jaffar M, Hambley T . The influence of tumour microenvironmental factors on the efficacy of cisplatin and novel platinum(IV) complexes. Biochem Pharmacol. 2005; 70(8):1137-46. DOI: 10.1016/j.bcp.2005.07.016. View

Newton H . Intra-arterial chemotherapy of primary brain tumors. Curr Treat Options Oncol. 2005; 6(6):519-30. DOI: 10.1007/s11864-005-0030-1. View

Modok S, Hyde P, Mellor H, Roose T, Callaghan R . Diffusivity and distribution of vinblastine in three-dimensional tumour tissue: experimental and mathematical modelling. Eur J Cancer. 2006; 42(14):2404-13. DOI: 10.1016/j.ejca.2006.05.020. View

Kartalou M, Essigmann J . Recognition of cisplatin adducts by cellular proteins. Mutat Res. 2001; 478(1-2):1-21. DOI: 10.1016/s0027-5107(01)00142-7. View

Tannock I, Lee C, Tunggal J, Cowan D, Egorin M . Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res. 2002; 8(3):878-84. View

Dolman R, Deacon G, Hambley T . Studies of the binding of a series of platinum(IV) complexes to plasma proteins. J Inorg Biochem. 2002; 88(3-4):260-7. DOI: 10.1016/s0162-0134(01)00360-9. View

10.

Siddik Z . Biochemical and molecular mechanisms of cisplatin resistance. Cancer Treat Res. 2002; 112:263-84. DOI: 10.1007/978-1-4615-1173-1_13. View

11.

Ilinski P, Lai B, Cai Z, Yun W, Legnini D, Talarico T . The direct mapping of the uptake of platinum anticancer agents in individual human ovarian adenocarcinoma cells using a hard X-ray microprobe. Cancer Res. 2003; 63(8):1776-9. View

12.

Hall M, Foran G, Zhang M, Beale P, Hambley T . XANES determination of the platinum oxidation state distribution in cancer cells treated with platinum(IV) anticancer agents. J Am Chem Soc. 2003; 125(25):7524-5. DOI: 10.1021/ja0354770. View

13.

Hall M, Martin C, Ferguson D, Phillips R, Hambley T, Callaghan R . Comparative efficacy of novel platinum(IV) compounds with established chemotherapeutic drugs in solid tumour models. Biochem Pharmacol. 2003; 67(1):17-30. DOI: 10.1016/j.bcp.2003.07.016. View

14.

Katano K, Safaei R, Samimi G, Holzer A, Tomioka M, Goodman M . Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clin Cancer Res. 2004; 10(13):4578-88. DOI: 10.1158/1078-0432.CCR-03-0689. View

15.

Hall M, Amjadi S, Zhang M, Beale P, Hambley T . The mechanism of action of platinum(IV) complexes in ovarian cancer cell lines. J Inorg Biochem. 2004; 98(10):1614-24. DOI: 10.1016/j.jinorgbio.2004.05.017. View

16.

Holzer A, Katano K, Klomp L, Howell S . Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res. 2004; 10(19):6744-9. DOI: 10.1158/1078-0432.CCR-04-0748. View

17.

Lottner C, Knuechel R, Bernhardt G, Brunner H . Distribution and subcellular localization of a water-soluble hematoporphyrin-platinum(II) complex in human bladder cancer cells. Cancer Lett. 2004; 215(2):167-77. DOI: 10.1016/j.canlet.2004.06.035. View

18.

Heldin C, Rubin K, Pietras K, Ostman A . High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004; 4(10):806-13. DOI: 10.1038/nrc1456. View

19.

Hicks K, Ohms S, van Zijl P, Denny W, Hunter P, Wilson W . An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br J Cancer. 1997; 76(7):894-903. PMC: 2228074. DOI: 10.1038/bjc.1997.481. View